ASTRO 2026 Highlights: PSMA PET Comparisons, Brain MRI in SCLC, and Neuroendocrine Theranostics

The ASTRO 2026 meeting featured imaging research including comparative studies of PSMA PET agents, routine brain MRI surveillance for patients with small-cell lung cancer, and early data on 177Lu-edotreotide for gastroenteropancreatic neuroendocrine tumors.

• Presentations included head-to-head comparisons of different PSMA-targeted PET tracers.
• One study examined the yield of surveillance brain MRI in patients with small-cell lung cancer.
• Early experience with 177Lu-edotreotide for GEP-NETs was shared.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.